[1]
B. Corona Prandi, M. P Rosim, G. Ogata Pedro, e M. Papadimitropoulos, “Cost per number needed to treat and treatment cost of baricitinib versus adalimumab on rheumatoid arthritis treatment in the brazilian private healthcare system ”, JAFF, vol. 4, nº s.1, fev. 2023.